LAROTRECTINIB
larotrectinib 25 mg capsule, 56
LAROTRECTINIB (13027P)
13027P
Manner of administration:Oral
Restriction
Indication: Solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene
fusion
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $2,637.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Vitrakvi | |||||